Clinical Trial Update: A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/Phase 2 clinical trial evaluating mavorixafor in participants with congenital neutropenia and chronic idiopathic neutropenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Neutropenia
• Idiopathic Neutropenia

Drugs mentioned

• Mavorixafor (mavorixafor)

Snippet

Sponsor: X4 Pharmaceuticals | Conditions: Neutropenia | Phase 1, Phase 2 | Status: COMPLETED